![]() |
|
|
Vol. 299, Issue 3, 1140-1147, December 2001
Division of Clinical Pharmacology, University Hospital (S.B.H.,
E.J., R.L.), and Division of Pharmacokinetics and Drug Therapy, Uppsala
University, Uppsala, Sweden (M.O.K.)
CHS 828 is a novel drug belonging to the cyanoguanidines. It has shown
promising anticancer activity in many preclinical systems and is
currently in early clinical trials. Our aim in this study was to assess
the growth inhibitory effect of CHS 828 in comparison with paclitaxel,
etoposide, and topotecan as a function of concentration and time. U937
GTB, RPMI 8226/S, MDA 231, primary cells from chronic lymphocytic
leukemia, and normal mononuclear cells were exposed to CHS 828 and U937 GTB cells were exposed to paclitaxel, etoposide, and topotecan
in 18 concentrations for times ranging from 1 to 72 h. Cell
survival was measured after 72-h incubation by using the fluorometric
microculture cytotoxicity assay. Nonlinear mixed effect modeling was
used to model the concentration-effect curves with a modified Hill
equation. Patterns of change of drug potency (IC50), slope
of the concentration-effect curves, and plateau with time were studied.
The log IC50 for CHS 828 decreased with log time in a
sigmoid manner for all cell types tested. Although very steep at short
and long incubation, the concentration-effect curves became shallow at
intermediate times. The log IC50 for etoposide and
topotecan was decreased with log time in a sigmoid manner. The log
IC50 for paclitaxel decreased linearly with log time. The
information obtained from modeling the cytotoxic effect of CHS 828 and
changes of IC50 and slope parameters with exposure time
suggests a heterogeneous cell response to CHS 828. This could indicate
two distinct mechanisms of induction of cell death.
This article has been cited by other articles:
![]() |
M. Bergstrom, A. Monazzam, P. Razifar, S. Ide, R. Josephsson, and B. Langstrom Modeling Spheroid Growth, PET Tracer Uptake, and Treatment Effects of the Hsp90 Inhibitor NVP-AUY922 J. Nucl. Med., July 1, 2008; 49(7): 1204 - 1210. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Gardner and M. Fernandes New tools for cancer chemotherapy: computational assistance for tailoring treatments Mol. Cancer Ther., October 1, 2003; 2(10): 1079 - 1084. [Abstract] [Full Text] |
||||
![]() |
P. Hovstadius, R. Larsson, E. Jonsson, T. Skov, A.-M. Kissmeyer, K. Krasilnikoff, J. Bergh, M. O. Karlsson, A. Lonnebo, and J. Ahlgren A Phase I Study of CHS 828 in Patients with Solid Tumor Malignancy Clin. Cancer Res., September 1, 2002; 8(9): 2843 - 2850. [Abstract] [Full Text] [PDF] |
||||